Merck
Trade Merck 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRK
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.
MRK Key Statistics
Stock Snapshot
With a market cap of 235.73B, Merck(MRK) trades at $94.95. The stock has a price-to-earnings ratio of 12.57 and currently yields dividends of 3.4%.
As of 2025-11-20, Merck(MRK) stock has fluctuated between $93.90 and $96.00. The current price stands at $94.95, placing the stock +1.1% above today's low and -1.1% off the high.
The Merck(MRK)'s current trading volume is 12.54M, compared to an average daily volume of 14.96M.
During the past year, Merck(MRK) stock moved between $73.31 at its lowest and $105.07 at its peak.
During the past year, Merck(MRK) stock moved between $73.31 at its lowest and $105.07 at its peak.
MRK News
The pharmaceutical giant's post-Keytruda plans continue to take shape. Over the past two years, Merck (MRK +0.06%) has faced several challenges, resulting in a...
Merck & Co. Inc. (NYSE:MRK) on Wednesday shared topline results from the Phase 3 trial of an investigational, once-daily, oral, two-drug, single-tablet regimen...
Merck (MRK) announced topline results from the pivotal double-blind Phase 3 trial of the investigational, once-daily, oral, two-drug, single-tablet regimen of d...
Analyst ratings
59%
of 29 ratingsMore MRK News
Merck (MRK) announced that the European Commission has approved a new subcutaneous, or under the skin, route of administration and a new pharmaceutical form of...
In November 2025, Merck announced a quarterly dividend increase and released positive clinical trial results for both WINREVAIR in pulmonary hypertension and en...
Merck & Co. Inc. (NYSE:MRK) on Tuesday released topline results from the Phase 2 CADENCE study of Winrevair (sotatercept-csrk) in adults for combined post- and...
In a report released yesterday, Tim Anderson from Bank of America Securities reiterated a Buy rating on Merck & Company, with a price target of $105.00. Meet Yo...
BofA analyst Tim Anderson raised the firm’s price target on Merck (MRK) to $105 from $98 and keeps a Buy rating on the shares. The Cidara (CDTX) deal is a “reas...
Merck (MRK) said it anticipates a commercial opportunity surpassing $5B from Cidara’s (CDTX) experimental flu drug, and does not expect it to require a review b...
As of Nov. 17, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading de...
